ESCMID Vaccines 2025 Highlights Podcast

In this episode [11.11], Medicom’s correspondent covers 5 presentations from the 6^th ESCMID conference on vaccines, held in Lisbon, Portugal, from 10-13 September 2025.

The topics discussed are:

1. Infants immunised with nirsevimab have a lower risk of respiratory-related recurrent hospitalisation

[00.36] Nirsevimab immunisation in infants led to a reduction in the risk of recurrent hospitalisation due to respiratory infections and in all-cause hospitalisation, according to a real-world analysis of over 12,000 infants in Spain, reported at the ESCMID Vaccines 2025 conference.

2. RSV immunisation: Maternal versus direct infant immunisation

[02.58] Multiple strategies are available to prevent RSV infections in infants, including monoclonal antibodies and vaccines. Prof. Simon Drysdale (University of Oxford, UK) reviewed the latest evidence on RSV immunisation in infants and pregnant women.

3. Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years

[04.41] PCV20 demonstrated effectiveness with substantial reductions in cases of invasive pneumococcal disease and all-cause pneumonia in a cohort of more than 16 million individuals aged ≥65 years, according to a presentation from the ESCMID Vaccines 2025 conference.

4. Wastewater poliovirus detections in Europe may reflect seasonal infection patterns rather than consistent importation

[07.05] Poliovirus was detected in sewage samples in 2024 in multiple European countries, including Germany, Spain, Finland, Poland, and the UK. Genetic analyses of the vaccine-derived poliovirus 2 (NIE-ZAS-1) indicated at least 1 year of circulation and were initially interpreted as evidence of multiple simultaneous importations. At  ESCMID Vaccines 2025, Dr Kimberley Hansford presented an alternative interpretation, based on poliovirus seasonality.

5. Where do alternative vaccine administration routes fit in the clinical landscape?

[09.00] The Intramuscular and subcutaneous routes are the traditional methods for vaccine delivery. Prof. Marien de Jonge (Radboud University Medical Center, The Netherlands) reviewed current data on vaccines administered via alternative routes.

Enjoy listening!

Copyright ©2025 Medicom Publishing Group



Posted on 3 October 202517 October 2025